However, in clinical practice, patients diagnosed with treatment-naïve EGFR-mutant NSCLC without severe BM symptoms tend to choose EGFR-TKIs as first-line therapy and defer brain RT. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.